Skip to Sidebar Skip to Content

Nuclera

Benchtop eProtein Discovery system that lets labs express and characterise proteins in days rather than months.

  • Biotech & Life Sciences
  • Series B+
  • Cambridge
Sector
Biotech & Life Sciences
Stage
Series B+
Based in
Cambridge
Founded
2013
Funding raised
$87m Series C (2024–2026); earlier round

Nuclera builds the eProtein Discovery system, a benchtop instrument and cartridge platform that lets researchers screen, express and purify proteins in their own lab within days, replacing lengthy outsourced workflows. The Cambridge company was started in 2013 by University of Cambridge PhD students Michael Chen and Gordon McInroy and serves pharmaceutical, biotech and academic groups working on drug discovery. Nuclera closed a $75m Series C in 2024 and extended it by $12m in January 2026, taking the round to $87m, led by Elevage Medical Technologies and Jonathan Milner with the British Business Bank and GK Goh. Recent milestones include a membrane protein workflow, a Cytiva collaboration and the first CRO installation at Domainex.

Team

  • Michael Chen, Co-founder & CEO
  • Gordon McInroy, Co-founder

Backed by

Add this profile to your website

Show this card on your own site. It reads “As seen on EP+” and links back to this page.

Paste it anywhere your site accepts HTML. Is this your startup? Request an update if the card is out of date.

← All UK startups · Is this your company? Request an update

More startups in the directory

Subscribe to Newsletter

UK startup news, founder stories and funding insight, straight to your inbox every week. Free.